Tomas Miranda-Aquino

Tomas Miranda-Aquino


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Reumatología Clínica
Verified
Journal Article
Closed access
TMTomas Miranda-Aquino
Tomas Miranda-Aquino
SPSilvia Esmeralda Pérez-Topete
Silvia Esmeralda Pérez-Topete
CGChristian González-Padilla
Christian González-Padilla
Jorge Eduardo Hernandez del RioJorge Eduardo Hernandez del Rio
Jorge Eduardo Hernandez del Rio
ÓLÓscar Sergio Lomelí-Sánchez
Óscar Sergio Lomelí-Sánchez
VGVerónica González-Díaz
Verónica González-Díaz

1 August 2022 in Global Heart
Verified
Journal Article
Open access
PDF file
SSSalvador V. Spina
Salvador V. Spina
MVMarcelo Luiz Vieira
Marcelo Luiz Vieira
CHCésar Jose Herrera
César Jose Herrera
AEAna G. Munera Echeverri
Ana G. Munera Echeverri
PRPamela Rojo
Pamela Rojo
RPRicardo Pignatelli
Ricardo Pignatelli
Describe the use and findings of cardiopulmonary imaging—chest X-ray (cX-ray), echocardiography (cEcho), chest CT (cCT), lung ultrasound (LUS), and/or cardiac magnetic resonance imaging (cMRI)—in COVID-19 hospitalizations in Latin America (LATAM). There is a lack of information on the images used and their findings during the SARS-CoV-2 pandemic in LATAM. Multicenter, prospective, observational study of COVID-19 inpatients, conducted from March to December 2020, from 12 high-complexity centers, in nine LATAM countries. Adults (>18 years) with at least one imaging modality performed, followed from admission until discharge and/or in-hospital death, were included. We studied 1,435 hospitalized patients (64% males) with a median age of 58 years classified into three regions: Mexico (Mx), 262; Central America and Caribbean (CAC), 428; and South America (SAm), 745. More frequent comorbidities were overweight/obesity, hypertension, and diabetes. During hospitalization, 58% were admitted to the ICU. The in-hospital mortality was 28%, and it was highest in Mx (37%). The most frequent images performed were cCT (61%), mostly in Mx and SAm, and cX-ray (46%), significant in CAC. The cEcho was carried out in 18%, similarly among regions, and LUS was carried out in 7%, with a higher frequently in Mx. Abnormal findings on the cX-ray were peripheral or basal infiltrates, and in cCT abnormal findings were the ground glass infiltrates, more commonly in Mx. In LUS, interstitial syndrome was the most abnormal finding, predominantly in Mx and CAC. Renal failure was the most prevalent complication (20%), predominant in Mx and SAm. Heart failure developed in 13%, predominant in Mx and CAC. Lung thromboembolism was higher in Mx while myocardial infarction was in CAC. Logistic regression showed associations of abnormal imaging findings and their severity, with comorbidities, complications, and evolution. The use and findings of cardiopulmonary imaging in LATAM varied between regions and had a great impact on diagnosis and prognosis.

1 October 2016 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
SPS.E. Pérez-Topete
S.E. Pérez-Topete
TMTomas Miranda-Aquino
Tomas Miranda-Aquino
JHJ.A. Hernández-Portales
J.A. Hernández-Portales
ResumenIntroducciónClostridium difficile (C. difficile) es un bacilo grampositivo, causa común de diarrea en el medio hospitalario; siendo la incidencia documentada hasta un 10%. Hay distintos medios para su detección sin embargo en nuestro medio, una prueba muy utilizada es el inmunoanálisis de toxinas A y B.Objetivos1) Estimar el valor predictivo positivo de la prueba de inmunoanálisis para detección de toxinas A y B de C. difficile; 2) establecer la incidencia de diarrea por C. difficile en el hospital, y 3) conocer los factores asociados más comunes.MétodosEstudio de prueba diagnóstica. Se incluyó a los pacientes con cuadro indicativo de diarrea por C. difficile de enero del 2010 a agosto del 2013, en el Hospital Christus Muguerza Alta Especialidad y con prueba de inmunoanálisis positiva, y que se comprobó por biopsia de colon y cultivo de muestra fecal para determinación de C. difficile.ResultadosSe analizó a 360 pacientes a los que se le solicitaron toxinas A y B, de los cuales 55 casos resultaron positivos; en 35 se demostró la presencia de C. difficile. La incidencia fue del 10.2% y el valor predictivo positivo (VPP) de la prueba de toxinas A y B de C. difficile fue de 0.64 (intervalo de confianza del 95%, 0.51-0.76). Se encontró que el uso de antibioticoterapia previa (n=29) y de inhibidores de bomba de protones (n=19) fue el factor asociado más común.ConclusionesLa incidencia de C. difficile en nuestro medio es similar a la literatura revisada; sin embargo, el VPP de la prueba de detección de toxinas A y B fue bajo.AbstractIntroductionClostridium difficile (C. difficile) is a Gram-positive bacillus that is a common cause of diarrhea in the hospital environment, with a documented incidence of up to 10%. There are different methods to detect it, but a widely used test in our environment is the immunoassay for toxins A and B.AimsThe aim of our study was to 1) estimate the positive predictive value of the immunoassay for the detection of the C. difficile toxins A and B, 2) to establish the incidence of C. difficile-associated diarrhea in the hospital, and 3) to know the most common associated factors.MethodsA diagnostic test accuracy study was conducted within the time frame of January 2010 to August 2013 at the Hospital Christus Muguerza® Alta Especialidad on patients with symptoms suggestive of C. difficile-associated diarrhea that had a positive immunoassay test and confirmation of C. difficile through colon biopsy and stool culture.ResultsThe immunoassay for toxins A and B was performed in 360 patients. Fifty-five of the cases had positive results, 35 of which showed the presence of C. difficile. Incidence was 10.2% and the positive predictive value of the test for C. difficile toxins A and B was 0.64 (95% CI, 0.51-0.76). Previous antibiotic therapy (n=29) and proton pump inhibitor use (n=19) were the most common associated factors.ConclusionsC. difficile incidence in our environment is similar to that found in the literature reviewed, but the positive predictive value of the test for toxin A and B detection was low

1 February 2021 in Reumatología Clínica
Verified
Journal Article
Closed access
SPSilvia Esmeralda Pérez-Topete
Silvia Esmeralda Pérez-Topete
TMTomas Miranda-Aquino
Tomas Miranda-Aquino
Jorge Eduardo Hernandez del RioJorge Eduardo Hernandez del Rio
Jorge Eduardo Hernandez del Rio
SCSergio Cerpa-Cruz
Sergio Cerpa-Cruz
SGSergio Ramón Gutiérrez-Ureña
Sergio Ramón Gutiérrez-Ureña
VGVerónica González-Díaz
Verónica González-Díaz

12 February 2026 in Life
Verified
Journal Article
Open access
PDF file
HMHaydee Ninette Morales-Vazquez
Haydee Ninette Morales-Vazquez
DMDavid Cardona Müller
David Cardona Müller
FPFernando Grover Páez
Fernando Grover Páez
CRCarlos Gerardo Ramos-Becerra
Carlos Gerardo Ramos-Becerra
EMErnesto Germán Cardona Muñoz
Ernesto Germán Cardona Muñoz
CGChristopher Josue Lopez Gradilla
Christopher Josue Lopez Gradilla
Background: Cardiac arrhythmias are a frequent complication of acute SARS-CoV-2 infection. However, their long-term prevalence and clinical determinants among patients with post-COVID-19 syndrome, especially those previously hospitalized, remain poorly defined. Objectives: To assess the prevalence and types of arrhythmias in long COVID patients following hospitalization and to identify associated clinical risk factors. Methods: In this cross-sectional study, 53 patients previously hospitalized with confirmed COVID-19 were evaluated ≥3 months post-infection. All participants underwent a standardized clinical assessment, 12-lead electrocardiography, and 24 h Holter monitoring. Logistic and Cox regression analyses were performed to identify predictors of arrhythmia. Results: Arrhythmias were identified in 41.5% (n = 22) of patients. Atrial fibrillation (32%) was the most frequent arrhythmia, followed by sinus bradycardia (27%) and sinus tachycardia (18%). Age (OR 1.06, 95% CI 1.01–1.10, p = 0.01) and length of hospital stay (OR 1.1, 95% CI 1.01–1.2, p = 0.04) were independently associated with arrhythmia. Biguanide (metformin) therapy was inversely associated with the occurrence of arrhythmia (Exp(B) = 0.017, p = 0.008). Dyspnea (82.4%) and palpitations (41.5%) were the most commonly reported symptoms. Conclusions: Arrhythmias are common in patients with long COVID following severe disease. Advanced age and prolonged hospitalization are significant risk factors, while biguanide use may offer a protective effect. These findings underscore the need for targeted cardiac surveillance in this population.

27 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IGItzel Elizabeth Garibay-Padilla
Itzel Elizabeth Garibay-Padilla
Jorge Eduardo Hernandez del RioJorge Eduardo Hernandez del Rio
Jorge Eduardo Hernandez del Rio
DODayana Estefania Orozco-Sepulveda
Dayana Estefania Orozco-Sepulveda
CPCHRISTIAN GONZALEZ PADILLA
CHRISTIAN GONZALEZ PADILLA
TMTomas Miranda-Aquino
Tomas Miranda-Aquino
Jaime Briseno-RamirezJaime Briseno-Ramirez
Jaime Briseno-Ramirez
Background/Objectives: Infective endocarditis (IE) carries substantial mortality, particularly in middle-income settings where patient profiles and microbial ecology differ from those of cohorts used to derive international prognostic scores. Syndrome-specific, locally grounded decision aids for empirical therapy are also scarce. We aimed to identify predictors of in-hospital mortality, externally evaluate the RiskE and ICE scores, and construct a Bayesian weighted-incidence syndromic combination antibiogram (WISCA) for IE. Methods: We conducted a retrospective cohort study of consecutive adults with definite or possible IE admitted between January 2019 and January 2026. Candidate predictors were screened in two phases and a clinically specified model was estimated with maximum-likelihood and Firth penalization, with 1000-replicate bootstrap optimism correction. Discrimination was compared against RiskE and ICE using DeLong’s test and reclassification metrics. For empirical coverage, we built a WISCA using identified pathogens, reporting both non-Bayesian bootstrap estimates and Bayesian hierarchical partial-pooling estimates with species- and antibiotic-level random intercepts; analyses were also stratified by IE type. Results: In-hospital mortality was 22.9%. Septic shock (Firth OR 9.23, 95% CI 2.40–40.61) and acute heart failure (OR 10.01, 95% CI 2.78–41.07) were the strongest independent predictors; the final model achieved an AUC of 0.922 (optimism-corrected 0.908) and outperformed RiskE (AUC 0.598) and ICE (AUC 0.632). Bayesian WISCA ranked vancomycin + gentamicin and meropenem + gentamicin highest (both 87.0%); several β-lactam–based combinations provided comparably high coverage without requiring routine carbapenems. Coverage was consistently higher for community-acquired than healthcare-associated IE. Conclusions: A simple variable model provided strong, locally valid mortality prediction and substantially outperformed international scores in this hemodialysis-predominant cohort. Bayesian WISCA offers stable, institution-specific empirical coverage estimates that can support stewardship-oriented regimen selection; multicenter validation is warranted.